{
    "nctId": "NCT01589159",
    "briefTitle": "A Phase \u2161 Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes",
    "officialTitle": "A Phase \u2161 Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Clinical benefit rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients between 18 and 65 years old\n* patients with metastatic breast cancer previousely treated with A/T\n* able and willing to give consent to participate in the study\n\nExclusion Criteria:\n\n* pregnant or lactating females\n* other tumor history\n* instable complication (e.g., myocardial infarction within 6 months,arrhythmia, unstable diabetes, hypercalcemia) or uncontrolled infection\n* concurrent disease or condition that would make the patient inappropriate for study participation\n* resist to participate in the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}